Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 1, 2012, Pages 127-138

  Wagner, Christian ^a   Jantratid, Ekarat ^a   Kesisoglou, Filippos ^b   Vertzoni, Maria ^c   Reppas, Christos ^c   B Dressman, Jennifer ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Absorption; Dissolution; Food effect; Permeability; Physiologically based pharmacokinetic model; Precipitation

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; N[4 [2 [[2 HYDROXY 2 (PYRIDINE 3 YL)ETHYL]AMINO]ETHYL]PHENYL] 4 [4 [4 (TRIFLUORO METHYLPHENYL]THIAZOL 2 YL]BENZENESULFONAMIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED DRUG RELEASE; DIET RESTRICTION; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PENETRATION; DRUG SOLUBILITY; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMEDIATE DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; INTESTINE MUCOSA PERMEABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN;

ADMINISTRATION, ORAL; CACO-2 CELLS; CHEMICAL PRECIPITATION; COMPUTER SIMULATION; FOOD-DRUG INTERACTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84866037370     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.05.008     Document Type: Article

References (79)

1. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 Suppl 2 2000 S73 S80
3. J.L. Ford The current status of solid dispersions Pharm. Acta Helv. 61 1986 69 88
4. P. Gupta, V.K. Kakumanu, and A.K. Bansal Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective Pharm. Res. 21 2004 1762 1769
5. B.C. Hancock, and G. Zografi Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1997 1 12
6. J.E. Patterson, M.B. James, A.H. Forster, R.W. Lancaster, J.M. Butler, and T. Rades The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds J. Pharm. Sci. 94 2005 1998 2012
7. A.T. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
8. A.T. Serajuddin Salt formation to improve drug solubility Adv. Drug Deliv. Rev. 59 2007 603 616
9. D. Fleisher, C. Li, Y. Zhou, L.H. Pao, and A. Karim Drug, meal and formulation interactions influencing drug absorption after oral administration Clin Implication, Clin. Pharmacokinet. 36 1999 233 254
10. B.N. Singh Effects of food on clinical pharmacokinetics Clin. Pharmacokinet. 37 1999 213 255
11. P.G. Welling Effects of food on drug absorption Annu. Rev. Nutr. 16 1996 383 415
12. D.R. de Campos, S. Klein, T. Zoller, N.R. Vieria, F.A. Barros, E.C. Meurer, E.C. Coelho, M.A. Marchioretto, and J. Pedrazzoli Evaluation of pantoprazole formulations in different dissolution apparatus using biorelevant medium Arzneimittelforschung 60 2010 42 47
13. J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms Pharm. Res. 15 1998 11 22
14. E. Jantratid, N. Janssen, H. Chokshi, K. Tang, and J.B. Dressman Designing biorelevant dissolution tests for lipid formulations: case example-lipid suspension of RZ-50 Eur. J. Pharm. Biopharm. 69 2008 776 785
15. V.P. Shah, J.J. Konecny, R.L. Everett, B. McCullough, A.C. Noorizadeh, and J.P. Skelly In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants Pharm. Res. 6 1989 612 618
16. V.H. Sunesen, B.L. Pedersen, H.G. Kristensen, and A. Mullertz In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media Eur. J. Pharm. Sci. 24 2005 305 313
17. S. Blanquet, E. Zeijdner, E. Beyssac, J.P. Meunier, S. Denis, R. Havenaar, and M. Alric A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions Pharm. Res. 21 2004 585 591
18. J. Brouwers, B. Anneveld, G.J. Goudappel, G. Duchateau, P. Annaert, P. Augustijns, and E. Zeijdner Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system Eur. J. Pharm. Biopharm. 77 2011 313 319
19. A. Mercuri, A. Passalacqua, M.S. Wickham, R.M. Faulks, D.Q. Craig, and S.A. Barker The effect of composition and gastric conditions on the self-emulsification process of ibuprofen-loaded self-emulsifying drug delivery systems: a microscopic and dynamic gastric model study Pharm. Res. 28 2011 1540 1551
20. M. Vardakou, A. Mercuri, S.A. Barker, D.Q. Craig, R.M. Faulks, and M.S. Wickham Achieving antral grinding forces in biorelevant in vitro models: comparing the USP dissolution apparatus II and the dynamic gastric model with human in vivo data AAPS PharmSciTech. 12 2011 620 626
21. M. Vardakou, A. Mercuri, T.A. Naylor, D. Rizzo, J.M. Butler, P.C. Connolly, M.S. Wickham, and R.M. Faulks Predicting the human in vivo performance of different oral capsule shell types using a novel in vitro dynamic gastric model Int. J. Pharm. 419 2011 192 199
22. K.A. Lentz Current methods for predicting human food effect AAPS J 10 2008 282 288
23. S.S. De Buck, V.K. Sinha, L.A. Fenu, M.J. Nijsen, C.E. Mackie, and R.A. Gilissen Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs Drug Metab. Dispos. 35 2007 1766 1780
24. G.M. Grass, and P.J. Sinko Physiologically-based pharmacokinetic simulation modelling Adv. Drug Deliv. Rev. 54 2002 433 451
25. H.M. Jones, N. Parrott, G. Ohlenbusch, and T. Lave Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling Clin. Pharmacokinet. 45 2006 1213 1226
26. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2010 257 264
27. J. Keldenich Measurement and prediction of oral absorption Chem. Biodivers. 6 2009 2000 2013
28. F. Kesisoglou, and Y. Wu Understanding the effect of API properties on bioavailability through absorption modeling AAPS J 10 2008 516 525
29. M. Kuentz, S. Nick, N. Parrott, and D. Rothlisberger A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 27 2006 91 99
30. A. Okumu, M. DiMaso, and R. Lobenberg Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products Eur. J. Pharm. Biopharm. 72 2009 91 98
31. N. Parrott, and T. Lave Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA Eur. J. Pharm. Sci. 17 2002 51 61
32. N. Parrott, V. Lukacova, G. Fraczkiewicz, and M.B. Bolger Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects AAPS J 11 2009 45 53
33. S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J.B. Dressman A physiological model for the estimation of the fraction dose absorbed in humans J. Med. Chem. 47 2004 4022 4031
34. X. Zhang, R.A. Lionberger, B.M. Davit, and L.X. Yu Utility of physiologically based absorption modeling in implementing quality by design in drug development AAPS J 13 2011 59 71
35. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
36. B. Kaeser, J.E. Charoin, M. Gerber, P. Oxley, H. Birnboeck, N. Saiedabadi, and L. Banken Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects Int. J. Clin. Pharmacol. Ther. 43 2005 154 162
37. D. Psachoulias, M. Vertzoni, K. Goumas, V. Kalioras, S. Beato, J. Butler, and C. Reppas Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults Pharm. Res. 28 2011 3145 3158
38. T.L. Russell, R.R. Berardi, J.L. Barnett, T.L. O'Sullivan, J.G. Wagner, and J.B. Dressman PH-related changes in the absorption of dipyridamole in the elderly Pharm. Res. 11 1994 136 143
39. R.J. Mathvink, J.S. Tolman, D. Chitty, M.R. Candelore, M.A. Cascieri, L.F. Colwell Jr., L. Deng, W.P. Feeney, M.J. Forrest, G.J. Hom, D.E. MacIntyre, R.R. Miller, R.A. Stearns, L. Tota, M.J. Wyvratt, M.H. Fisher, and A.E. Weber Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide J. Med. Chem. 43 2000 3832 3836
40. R.A. Stearns, R.R. Miller, W. Tang, G.Y. Kwei, F.S. Tang, R.J. Mathvink, E.M. Naylor, D. Chitty, V.J. Colandrea, A.E. Weber, A.E. Colletti, J.R. Strauss, C.A. Keohane, W.P. Feeney, S.A. Iliff, and S.H. Chiu The pharmacokinetics of a thiazole benzenesulfonamide beta 3-adrenergic receptor agonist and its analogs in rats, dogs, and monkeys: improving oral bioavailability Drug Metab. Dispos. 30 2002 771 777
41. W. Tang, R.A. Stearns, R.R. Miller, J.S. Ngui, R.J. Mathvink, A.E. Weber, G.Y. Kwei, J.R. Strauss, C.A. Keohane, G.A. Doss, S.H. Chiu, and T.A. Baillie Metabolism of a thiazole benzenesulfonamide derivative, a potent and elective agonist of the human beta3-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate Drug Metab. Dispos. 30 2002 778 787
42. M. Camilleri Integrated upper gastrointestinal response to food intake Gastroenterology 131 2006 640 658
43. D.G. Bailey, J.M. Arnold, C. Munoz, and J.D. Spence Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin Clin. Pharmacol. Ther. 53 1993 637 642
44. D.G. Bailey, and G.K. Dresser Grapefruit juice-lovastatin interaction Clin. Pharmacol. Ther. 67 2000 690
45. H.H. Kupferschmidt, H.R. Ha, W.H. Ziegler, P.J. Meier, and S. Krahenbuhl Interaction between grapefruit juice and midazolam in humans Clin. Pharmacol. Ther. 58 1995 20 28
46. J.J. Lilja, K.T. Kivisto, and P.J. Neuvonen Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin Clin. Pharmacol. Ther. 66 1999 118 127
47. G.C. Yee, D.L. Stanley, L.J. Pessa, T. Dalla Costa, S.E. Beltz, J. Ruiz, and D.T. Lowenthal Effect of grapefruit juice on blood cyclosporin concentration Lancet 345 1995 955 956
48. M. Martinez, G. Amidon, L. Clarke, W.W. Jones, A. Mitra, and J. Riviere Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations Adv. Drug Deliv. Rev. 54 2002 825 850
49. C.J. Porter, and W.N. Charman Intestinal lymphatic drug transport: an update Adv. Drug Deliv. Rev. 50 2001 61 80
50. B.G. Boggiano, and M. Gleeson Gastric acid inactivation of erythromycin stearate in solid dosage forms J. Pharm. Sci. 65 1976 497 502
51. A.A. Somogyi, F. Bochner, D. Hetzel, and D.B. Williams Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin Pharm. Res. 12 1995 149 154
52. R. Sankar, N. Sharda, and S. Singh Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3 Drug Dev. Ind. Pharm. 29 2003 733 738
53. C.K. Svensson, D.J. Edwards, P.M. Mauriello, S.H. Barde, A.C. Foster, R.A. Lanc, E. Middleton Jr., and D. Lalka Effect of food on hepatic blood flow: implications in the "food effect" phenomenon Clin. Pharmacol. Ther. 34 1983 316 323
54. W.N. Charman, and V.J. Stella Transport of lipophilic molecules by the intestinal lymphatic system Adv. Drug Deliv. Rev. 7 1991 1 14
55. W.N.A. Charman, and V.J. Stella Estimating the maximal potential for intestinal lymphatic transport of lypophilic drug molecules Int. J. Pharm. 34 1986 175 178
56. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
57. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm. 60 2005 413 417
58. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 1998 698 705
59. A. Glomme, J. Marz, and J.B. Dressman Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities J. Pharm. Sci. 94 2005 1 16
60. S. Klein, and V.P. Shah A standardized mini paddle apparatus as an alternative to the standard paddle AAPS PharmSciTech. 9 2008 1179 1184
61. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51
62. G.M. Grass Simulation models to predict oral drug absorption from in vitro data Adv. Drug Deliv. Rev. 23 1997 199 219
63. C. Schiller, C.P. Frohlich, T. Giessmann, W. Siegmund, H. Monnikes, N. Hosten, and W. Weitschies Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment Pharmacol. Ther. 22 2005 971 979
64. N. Fotaki, M. Symillides, and C. Reppas Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration Eur. J. Pharm. Sci. 26 2005 324 333
65. U. Fagerholm The role of permeability in drug ADME/PK, interactions and toxicity-presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans Pharm. Res. 25 2008 625 638
66. J.P. Wilson Surface area of the small intestine in man Gut 8 1967 618 621
67. P. Costa, and J.M. Sousa Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
68. S.A. Marston, and J.E. Polli Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence Pharm. Res. 14 1997 1363 1369
69. FDA, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. < http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.pdf >.
70. P.E. Macheras, M.A. Koupparis, and S.G. Antimisiaris Drug binding and solubility in milk Pharm. Res. 7 1990 537 541
71. B. Abrahamsson, T. Albery, A. Eriksson, I. Gustafsson, and M. Sjoberg Food effects on tablet disintegration Eur. J. Pharm. Sci. 22 2004 165 172
72. S. Anwar, J.T. Fell, and P.A. Dickinson An investigation of the disintegration of tablets in biorelevant media Int. J. Pharm. 290 2005 121 127
73. L. Kalantzi, B. Polentarutti, T. Albery, D. Laitmer, B. Abrahamsson, J. Dressman, and C. Reppas The delayed dissolution of paracetamol products in the canine fed stomach can be predicted in vitro but it does not affect the onset of plasma levels Int. J. Pharm. 296 2005 87 93
74. S. Carlert, A. Palsson, G. Hanisch, C. von Corswant, C. Nilsson, L. Lindfors, H. Lennernas, and B. Abrahamsson Predicting intestinal precipitation - a case example for a basic BCS class II drug Pharm. Res. 27 2010 2119 2130
75. Y. Shono, E. Jantratid, and J.B. Dressman Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: Case example nelfinavir Eur. J. Pharm. Biopharm. 2011
76. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, and J.B. Dressman Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans Eur. J. Pharm. Biopharm. 2010
77. M.C. Gres, B. Julian, M. Bourrie, V. Meunier, C. Roques, M. Berger, X. Boulenc, Y. Berger, and G. Fabre Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line Pharm. Res. 15 1998 726 733
78. I.J. Hidalgo, T.J. Raub, and R.T. Borchardt Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability Gastroenterology 96 1989 736 749
79. W. Rubas, N. Jezyk, and G.M. Grass Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption Pharm. Res. 10 1993 113 118